Analysis of mechanisms contributing to AraC-mediated chemoresistance and re-establishment of drug sensitivity by the novel heterodinucleoside phosphate 5-FdUrd-araC

Apoptosis

Volumn 11, Issue 3, 2006, Pages 427-440

  Maier, S ^a   Strasser, S ^a   Saiko, P ^b   Leisser, C ^a   Sasgary, S ^c   Grusch, M ^c   Madlener, S ^a   Bader, Y ^a   Hartmann, J ^a   Schott, H ^d   Mader, R M ^b   Szekeres, T ^b   Fritzer Szekeres, M ^b   Krupitza, G ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS INDUCING FACTOR; CASPASE 7; CYCLIN D1; CYTARABINE; DINUCLEOSIDE PHOSPHATE; DOXORUBICIN; FLOXURIDINE; PHOSPHATE; PRODRUG; PROTEIN P21; PROTEIN P27; PROTEIN P53;

APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL CYCLE; CELL STRAIN MCF 7; CELL SURVIVAL; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG ACTIVATION; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG SENSITIVITY; GENE EXPRESSION; GENE INDUCTION; HOMEOSTASIS; HUMAN; HUMAN CELL; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STRESS; TUMOR SUPPRESSOR GENE;

ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CYTARABINE; DRUG RESISTANCE, NEOPLASM; FEMALE; FLOXURIDINE; HUMANS; MOLECULAR STRUCTURE;

MINK CELL FOCUS-FORMING VIRUS;

EID: 33646427699     PISSN: 13608185     EISSN: 1573675X     Source Type: Journal    
DOI: 10.1007/s10495-006-4066-x     Document Type: Article

References (35)

1. Momparler RL. A model for the chemotherapy of acute leukemia with 1-beta-D- arabinofuranosylcytosine. Cancer Res 1974; 34(8): 1775-1787.
2. Early AP, Preisler HD, Slocum H, Rustum YM. A pilot study of high-dose 1-beta-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology. Cancer Res 1982; 42(4): 1587-94.
3. Saiko P, Horvath Z, Illmer C, Madlener S, et al. Cytotoxic effects of novel amphiphilic dimers consisting of 5-fluorodeoxyuridine and arabinofuranosylcytosine in cross-resistant H9 human lymphoma cells. Leuk Res 2005; 29(7): 785-791.
4. Blum JL, Jones SE, Buzdar AU, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999; 17(2): 485-493.
5. Talbot DC, Moiseyenko V, Van Belle S, et al. Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. Br J Cancer 2002; 86(9): 1367-1372.
6. Oshaughnessy JA, Blum J, Moiseyenko V, et al. Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol 2001; 12(9): 1247-1254.
7. Saiko P, Horvath Z, Bauer W, et al. In vitro and in vivo antitumor activity of novel amphiphilic dimers consisting of 5 -fluorodeoxyuridine and arabinofuranosylcytosine. Int J Oncol 2004; 25(2): 357-364.
8. Agarwal RP, Han T, Fernandez M. Reduced cellular transport and activation of fluoropyrimidine nucleosides and resistance in human lymphocytic cell lines selected for arabinosylcytosine resistance. Biochem Pharmacol 2001; 61(1): 39-47.
9. Bhalla K, Nayak R, Grant S. Isolation and characterization of a deoxycytidine kinase-deficient human promyelocytic leukemic cell line highly resistant to 1-beta-D- arabinofuranosylcytosine. Cancer Res 1984; 44(11): 5029-5037.
10. Wilkinson DS, Crumley J. Metabolism of 5-fluorouracil in sensitive and resistant Novikoff hepatoma cells. J Biol Chem 1977; 252(3): 1051-1056.
11. Cattaneo-Pangrazzi RM, Schott H, Schwendener RA. The novel heterodinucleoside dimer 5-FdU-NOAC is a potent cytotoxic drug and a p53-independent inducer of apoptosis in the androgen-independent human prostate cancer cell lines PC-3 and DU-145. Prostate 2000; 45(1): 8-18.
12. Eliyahu D, Michalovitz D, Oren M. Overproduction of p53 antigen makes established cells highly tumorigenic. Nature 1985; 316(6024): 158-160.
13. Michalovitz D, Halevy O, Oren M. Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell 1990; 62(4): 671-680.
14. Venditti JM, Wesley RA, Plowman J. Current NCI preclinical antitumor screening in vivo: results of tumor panel screening, 1976-1982, and future directions. Adv Pharmacol Chemother 1984; 20: 1-20.
15. Weinstein JN, Myers TG, O'Connor PM, et al. An information-intensive approach to the molecular pharmacology of cancer. Science 1997; 275(5298): 343-349.
16. Gudas J, Nguyen H, Li T, Hill D, Cowan KH. Effects of cell cycle, wild-type p53 and DNA damage on p21CIP1/Waf1 expression in human breast epithelial cells. Oncogene 1995; 11(2): 253-261.
17. Suzuki A, Toi M, Yamamoto Y, Saji S, Muta M, Tominaga T. Role of MDM2 overexpression in doxorubicin resistance of breast carcinoma. Jpn J Cancer Res 1998; 89(2): 221-227.
18. Andres JL, Fan S, Turkel GJ, et al. Regulation of BRCA1 and BRCA2 expression in human breast cancer cells by DNA-damaging agents. Oncogene 1998; 16(17): 2229-2241.
19. Asada N, Tsuchiya H, Tomita K. De novo deletions of p53 gene and wild-type p53 correlate with acquired cisplatin-resistance in human osteosarcoma OST cell line. Anticancer Res 1999; 19(6B): 5131-5137.
20. Mc Gee MM, Hyland E, Campiani G, Ramunno A, Nacci V, Zisterer DM. Caspase-3 is not essential for DNA fragmentation in MCF-7 cells during apoptosis induced by the pyrrolo-1,5-benzoxazepme, PBOX-6. FEBS Lett 2002; 515(1-3): 66-70.
21. Hu CC, Tang CH, Wang JJ. Caspase activation in response to cytotoxic Rana catesbeiana ribonuclease in MCF-7 cells. FEBS Lett 2001; 503(1): 65-68.
22. Pirnia F, Breuleux M, Schneider E, et al. Uncertain identity of doxorubicin-resistant MCF-7 cell lines expressing mutated p53. J Natl Cancer Inst 2000; 92(18): 1535-1536.
23. Liu XM, Wang LG, Kreis W, Budman DR, Adams LM. Differential effect of vinorelbine versus paclitaxel on ERK2 kinase activity during apoptosis in MCF-7 cells. Br J Cancer 2001; 85(9): 1403-1411.
24. Germain M, Affar EB, D'Amours D, Dixit VM, Salvesen GS, Poirier GG. Cleavage of automodified poly(ADP-ribose) polymerase during apoptosis. Evidence for involvement of caspase-7. J Biol Chem 1999; 274(40): 28379-28384.
25. Janicke RU, Ng P, Sprengart ML, Porter AG. Caspase-3 is required for alpha-fodrin cleavage but dispensable for cleavage of other death substrates in apoptosis. J Biol Chem 1998; 273(25): 15540-15545.
26. Daugas E, Susin SA, Zamzami N, et al. Mitochondrio-nuclear translocation of AIF in apoptosis and necrosis. Faseb J 2000; 14(5): 729-739.
27. Szekeres T, Schuchter K, Chiba P, et al. Synergistic action of tiazofurin with hypoxanthine and allopurinol in human neuroectodermal tumor cell lines. Biochem Pharmacol 1993; 46(11): 1903-1907.
28. Cozzarelli NR. The mechanism of action of inhibitors of DNA synthesis. Annu Rev Biochem 1977; 46: 641-668.
29. Bergman AM, Kuiper CM, Voorn DA, et al. Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinofuranosylcytosine in leukemia and solid tumor cell lines. Biochem Pharmacol 2004; 67(3): 503-511.
30. Cheng YC, Nakayama K. Effects of 5-fluoro-2′-deoxyuridine on DNA metabolism in HeLa cells. Mol Pharmacol 1983; 23(1): 171-174.
31. Furth JJ, Cohen SS. Inhibition of mammalian DNA polymerase by the 5′-triphosphate of 1-beta-d-arabinofuranosylcytosine and the 5′-triphosphate of 9-beta-d-arabinofuranoxyladenine. Cancer Res 1968; 28(10): 2061-2067.
32. Kufe DW, Major PP, Egan EM, Beardsley GP. Correlation of cytotoxicity with incorporation of ara-C into DNA. J Biol Chem 1980; 255(19): 8997-9000.
33. Parker WB, Cheng YC. Metabolism and mechanism of action of 5-fluorouracil. Pharmacol Ther 1990; 48(3): 381-395.
34. van Laar JA, Rustum YM, Ackland SP, van Groeningen CJ, Peters GJ. Comparison of 5-fluoro-2′-deoxyuridine with 5-fluorouracil and their role in the treatment of colorectal cancer. Eur J Cancer 1998; 34(3): 296-306.
35. Wang Z, He Q, Liang Y, Wang D, Li Y, Li D. Non-caspase-mediated apoptosis contributes to the potent cytotoxicity of the enediyne antibiotic lidamycin toward human tumor cells. Biochem Pharmacol 2003; 65: 1767-1775.